What's in Baxter Healthcare Corporation's pipeline?

Baxter Healthcare Corporation has 13 drugs in our index: 3 marketed, 0 filed, 7 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Baxter Healthcare Corporation's portfolio?

Top competitors by shared drug class: Brigham and Women's Hospital, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Universitaire de Nice, Coalition for National Trauma Research, Department of Medical Services Ministry of Public Health of Thailand.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/baxter-healthcare-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Baxter Healthcare Corporation — Portfolio Competitive Intelligence Brief

Baxter Healthcare Corporation pipeline: 3 marketed, 0 filed, 7 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 7 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
multiple electrolyte solution	multiple electrolyte solution	marketed	Electrolyte replacement solution		Critical Care / Fluid and Electrolyte Management
Fibrin Sealant	Fibrin Sealant	marketed
Clinolipid	Clinolipid	marketed			Metabolic
FS VH S/D 4 s-apr	FS VH S/D 4 s-apr	phase 3	Fresh frozen plasma (pathogen-reduced)		Hematology / Transfusion Medicine
Ped3CB	Ped3CB	phase 3	Sodium-potassium pump inhibitor	Na+/K+-ATPase	Cardiovascular
Paracetamol 1% solution	Paracetamol 1% solution	phase 3	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms	Pain Management
TISSEEL Lyo	TISSEEL Lyo	phase 3	Fibrin sealant		Surgical Hemostasis
FS VH S/D 500 s-apr	FS VH S/D 500 s-apr	phase 3	Blood product / Plasma derivative		Hematology / Transfusion Medicine
Fibrin Sealant VH S/D	Fibrin Sealant VH S/D	phase 3	Hemostatic agent / Fibrin sealant	Fibrinogen (substrate); thrombin (enzyme)	Surgery / Hemostasis
TISSEEL VH fibrin sealant	TISSEEL VH fibrin sealant	phase 3	Fibrin sealant	Fibrinogen; Thrombin substrate	Surgery/Hemostasis

Therapeutic area mix

Hematology / Transfusion Medicine · 2
Critical Care / Fluid and Electrolyte Management · 1
Metabolic · 1
Pain Management · 1
Surgery / Hemostasis · 1
Surgery/Hemostasis · 1
Cardiovascular · 1
Surgical Hemostasis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Brigham and Women's Hospital · 1 shared drug class
Centre Hospitalier Universitaire Dijon · 1 shared drug class
Centre Hospitalier Universitaire de Nice · 1 shared drug class
Coalition for National Trauma Research · 1 shared drug class
Department of Medical Services Ministry of Public Health of Thailand · 1 shared drug class
Erasmus Medical Center · 1 shared drug class
Ethicon, Inc. · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Baxter Healthcare Corporation:

Cite this brief

Drug Landscape (2026). Baxter Healthcare Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/baxter-healthcare-corporation. Accessed 2026-05-16.